Vircell has developed and launched two new VirClia monotest kits for the detection of novel Coronavirus COVID-19 antibodies in human serum and plasma.
There are two kits available for the VirClia automated CLIA system which are able to detect IgG or IgM + IgA antibodies from serum or plasma to COVID-19 infections. The tests have been developed and evaluated in Spain and are CE marked. The assays are intended to be used to show antibody response and immune status following COVID-19 infection.
Key Points
• Two assays are available based on VirClia monotest technology
• The COVID-19 IgG and IgM + IgA detection assays are run as an automated method on VirClia systems.
• The assays use a mix of COVID-19 recombinant nucleocapsid and spike glycoprotein antigens
• Results available in 40 minutes to 2 hours
Product Codes
• COVID-19 VirClia IgG Monotest (24 tests) Ref: VCM097
• COVID-19 VirClia IgM+IgA Monotest (24 tests) Ref: VCM098
For more information visit: VirClia – CLIA monotest system for infectious disease serology testing
